21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting HDLBP could help treat atherosclerosis in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). In 10 NAFLD patients, 10 NASH patients and 5...